Income Statement (TTM)
TriSalus Life Sciences, Inc. - Equity Warrant Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 12-31 |
2021 12-31 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 8 | 12 | 12 | 13 | 15 | 16 | 19 | 22 | 25 | 27 | 29 | 32 | 36 |
| Change (%) | 54.60 | 39.72 | 5.62 | 4.95 | 13.33 | 8.61 | 15.58 | 18.76 | 12.52 | 8.71 | 9.45 | 9.21 | 11.98 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 2 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 6 |
| Change (%) | -45.72 | 23.72 | 52.98 | 12.67 | 16.00 | -3.80 | -8.24 | 11.86 | 4.80 | 13.59 | 18.28 | 12.77 | 19.23 | |
| % of Revenue | 40.45 | 14.20 | 12.57 | 18.21 | 19.55 | 20.01 | 17.73 | 14.07 | 13.26 | 12.35 | 12.90 | 13.94 | 14.40 | 15.33 |
| Gross Operating Profit | 3 | 7 | 10 | 10 | 10 | 12 | 13 | 16 | 19 | 22 | 23 | 25 | 28 | 30 |
| Change (%) | 122.74 | 42.37 | -1.19 | 3.23 | 12.68 | 11.72 | 20.71 | 19.89 | 13.70 | 8.03 | 8.14 | 8.63 | 10.75 | |
| % of Revenue | 59.55 | 85.80 | 87.43 | 81.79 | 80.45 | 79.99 | 82.27 | 85.93 | 86.74 | 87.65 | 87.10 | 86.06 | 85.60 | 84.67 |
| SG&A | 13 | 17 | 22 | 25 | 27 | 30 | 33 | 36 | 41 | 42 | 42 | 44 | 44 | 47 |
| Change (%) | 30.32 | 28.14 | 15.67 | 6.67 | 10.22 | 9.65 | 11.47 | 12.45 | 3.80 | -0.63 | 4.19 | 0.89 | 6.47 | |
| % of Revenue | 240.28 | 202.55 | 185.76 | 203.43 | 206.76 | 201.10 | 203.02 | 195.81 | 185.40 | 171.03 | 156.34 | 148.84 | 137.51 | 130.75 |
| R&D | 16 | 14 | 19 | 21 | 22 | 24 | 28 | 30 | 30 | 28 | 22 | 18 | 15 | 14 |
| Change (%) | -10.12 | 36.83 | 9.74 | 4.10 | 6.05 | 20.16 | 5.30 | 0.68 | -7.31 | -19.19 | -21.38 | -14.41 | -4.91 | |
| % of Revenue | 291.22 | 169.31 | 165.80 | 172.27 | 170.87 | 159.90 | 176.90 | 161.17 | 136.63 | 112.55 | 83.66 | 60.10 | 47.10 | 40.00 |
| OpEx | 31 | 32 | 43 | 49 | 52 | 56 | 64 | 69 | 74 | 73 | 68 | 66 | 64 | 67 |
| Change (%) | 4.35 | 31.79 | 14.26 | 5.82 | 8.71 | 13.36 | 7.85 | 7.31 | -0.69 | -7.09 | -3.55 | -2.49 | 4.70 | |
| % of Revenue | 571.95 | 386.06 | 364.13 | 393.91 | 397.18 | 381.01 | 397.65 | 371.06 | 335.29 | 295.93 | 252.91 | 222.88 | 199.01 | 186.08 |
| Operating Income | -26 | -24 | -31 | -36 | -39 | -41 | -48 | -50 | -52 | -48 | -41 | -36 | -32 | -31 |
| Change (%) | -6.29 | 29.01 | 17.53 | 6.12 | 7.16 | 15.04 | 5.25 | 3.09 | -6.30 | -15.16 | -12.05 | -12.01 | -2.65 | |
| % of Revenue | -471.95 | -286.06 | -264.13 | -293.91 | -297.18 | -281.01 | -297.65 | -271.06 | -235.29 | -195.93 | -152.91 | -122.88 | -99.01 | -86.08 |
| Interest Expense | -6 | -2 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -2 | -3 | -4 | -5 |
| Change (%) | -70.83 | -87.68 | -99.54 | 500.00 | 66.67 | 40.00 | 14.29 | -12.50 | 6,235.71 | 128.30 | 52.59 | 39.03 | 12.71 | |
| % of Revenue | -111.12 | -20.96 | -1.85 | -0.01 | -0.05 | -0.07 | -0.09 | -0.09 | -0.06 | -3.59 | -7.53 | -10.50 | -13.37 | -13.45 |
| Net Income | -32 | -29 | -32 | -47 | -48 | -53 | -46 | -59 | -64 | -55 | -56 | -30 | -27 | -31 |
| Change (%) | -9.38 | 9.57 | 49.30 | 0.84 | 11.13 | -12.50 | 28.31 | 8.32 | -15.00 | 1.68 | -45.94 | -9.42 | 14.54 | |
| % of Revenue | -585.76 | -343.35 | -269.26 | -380.60 | -365.68 | -358.59 | -288.87 | -320.69 | -292.49 | -220.97 | -206.67 | -102.09 | -84.67 | -86.61 |
Source: Capital IQ
